ARCH Venture Fund IX, L.P. - Dec 31, 2024 SCHEDULE 13G/A Report for Beam Therapeutics Inc. Common Stock par value $0.01 per share (BEAM)

Filing Manager
ARCH Venture Fund IX, L.P.
Reporting Manager
Robert Nelsen
Security
Beam Therapeutics Inc. Common Stock par value $0.01 per share
Symbol
BEAM
Shares outstanding
82.2M shares
Disclosed Ownership
4.6M shares
Ownership
5.6%
Form type
SCHEDULE 13G/A
Date filed
2/14/2025, 04:55 PM
Date of event
Dec 31, 2024
Next filing
May 15, 2025
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ARCH Venture Fund IX, L.P. 5.5% 4.54M 0 4.54M ARCH Venture Partners IX, L.P. its General Partner
ARCH Venture Fund IX Overage, L.P. 5.5% 4.54M 0 4.54M ARCH Venture Partners IX Overage, L.P. its General Partner
ARCH Venture Partners IX, L.P. 5.5% 4.54M 0 4.54M ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX Overage, L.P. 5.5% 4.54M 0 4.54M ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX, LLC 5.5% 4.54M 0 4.54M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Keith Crandell 5.5% 4.56M 17.7K 4.54M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Clinton Bybee 5.5% 4.55M 10.5K 4.54M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Robert Nelsen 5.6% 4.6M 60.6K 4.54M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen